We are presenting new data on SRF388, a first in class IL-27 blocking antibody in clinical trials for patients with cancer at the @CytokineSociety conference this weekend! Read the full details here: https://t.co/LNq07iXAyO
#Cytokines2020 https://t.co/f1g61piSkN